Martin "M" Zenni, M.D.

Martin "M" Zenni M.D.

Associate Professor & Medical Director, Cardiovascular Off Campus Outreach Program; Medical Director of Nuclear Cardiology

Department: Department of Medicine
Business Phone: (904) 244-3378
Business Email: martin.zenni@jax.ufl.edu
Appointments and Locations

Board Certifications

  • Internal Medicine
  • Cardiovascular Disease
  • Interventional Cardiology
  • Nuclear Cardiology

Clinical Profile

Specialties
  • Cardiovascular Disease
  • Interventional Cardiology
  • Nuclear Cardiology
Interests
  • Clinical Special Interests: Coronary artery disease, atherosclerosis, hyperlipidemia and cardiac risk assessment; permanent pacemaker and hypothermia therapy for acute myocardial infarction; nuclear cardiology, antiplatelet and anticoagulant therapy
  • Research Special Interests: Coronary artery disease, atherosclerosis, hyperlipidemia and cardiac risk assessment, permanent pacemaker, and hypothermia therapy for acute myocardial infarction; nuclear cardiology, antiplatelet and anticoagulant therapy
Publications

Please note: The resulting entries may not reflect a complete or accurate listing for Martin "M" Zenni. Many journals are not indexed by PubMed, and there may be articles by other authors of the same name listed by this search.

Office Information

Academic Office
5th Floor, Ambulatory Care Center
655 West 8th Street, C35
Jacksonville, FL 32209
(904) 244-3101
 martin.zenni@jax.ufl.edu
Administrative Manager
 Eva Jones
(904) 244-3378
eva.jones@jax.ufl.edu

Clincal Research

OPEN ENROLLMENT
16US01: A Prospective Study of the BioFreedom™ Biolimus A9TM Drug Coated Stent in Patients at High Risk for Bleeding (Leaders Free II)
OPEN ENROLLMENT
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesion (ABSORB III)
OPEN ENROLLMENT
COBRA 2015-01 Randomized Trial of Cobra PzF Stenting to Reduce Duration of Triple Therapy (COBRA-REDUCE)
OPEN ENROLLMENT
Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a Rivaroxaban-based Antithrombotic Strategy to an Antiplatelet-based Strategy After Transcatheter Aortic Valve Replacement (TAVR) to Optimize Clinical Outcomes

Education

Medical Education
University of Chicago Pritzker School of Medicine, Chicago, IL, USA
Residency
Internal Medicine, Tufts-New England Medical Center, Boston, MA, USA
Fellowship
Cardiovascular Disease, Harvard Medical School, Boston, MA, USA
Fellowship
Interventional Cardiology, Harvard Medical School, Boston, MA, USA

News

February 03, 2020
Getting a Second Chance at Life
October 23, 2015
Several faculty recognized for longstanding service at UFCOMJ
March 10, 2015
Saving a lifesaver
February 28, 2012
UF Cardiovascular Center now open at Emerson Medical Plaza

Multimedia

September 28, 2020
Cardiovascular Disease Fellowship Program